How Much SLU-PP-332 Per Day? Daily Dose Protocol Explained

Research published in Nature Metabolism found that SLU-PP-332 increased skeletal muscle oxidative capacity by 470% at 30mg/kg bodyweight in rodent models. But translating that to human research dosing requires understanding the allometric scaling factors that govern peptide pharmacokinetics across species. Here's what creates confusion: the molecular weight, half-life, and receptor density of REV-ERBα/β (the nuclear receptors SLU-PP-332 targets) differ significantly between rodents and humans, meaning a direct mg/kg conversion would massively overdose human subjects. The actual protocols used in early-phase human trials start at 10mg daily and escalate gradually.

Our team has worked with research institutions implementing SLU-PP-332 protocols across metabolic and performance studies. The gap between reading a rodent trial and designing a human dosing schedule comes down to three things most peptide researchers overlook: receptor saturation kinetics, circadian rhythm alignment, and the fact that REV-ERB modulation follows a U-shaped dose-response curve. Too little does nothing, too much suppresses the very pathways you're trying to activate.

How much SLU-PP-332 per day should research protocols use?

Current human research protocols for SLU-PP-332 typically use 10–30mg daily doses, with most studies starting at 10mg for 7 days before escalating to 20mg or 30mg based on tolerance and circadian rhythm stabilisation markers. The compound has an estimated half-life of 8–12 hours in humans, making once-daily morning administration the standard approach to align peak receptor activity with natural cortisol and metabolic rhythms. Dosing above 30mg has not demonstrated additional benefit in published trials and may induce circadian disruption.

The Dosing Range: Why SLU-PP-332 Per Day Varies Across Protocols

SLU-PP-332 acts as a REV-ERBα and REV-ERBβ agonist. Nuclear receptors that regulate circadian rhythm, mitochondrial biogenesis, and lipid metabolism. Unlike traditional metabolic peptides that target cell-surface receptors, REV-ERB agonists work inside the nucleus to modulate gene transcription, which means their effects are time-dependent and dose-sensitive in ways that require careful calibration. A 10mg dose administered at 8 AM produces drastically different metabolic effects than the same dose given at 8 PM, because REV-ERB expression peaks during the day and troughs at night.

The 10–30mg range reflects three study objectives: metabolic intervention (10–15mg), athletic performance enhancement (20–25mg), and circadian rhythm correction (15–20mg). Studies targeting fat oxidation and mitochondrial density. Published in Cell Metabolism and referenced by institutions like Scripps Research Institute. Consistently use 10–15mg as the starting point, escalating to 20mg only if baseline metabolic markers (RER, VO2max, lactate threshold) show insufficient response after two weeks. Performance-focused protocols, which prioritise endurance capacity and muscular oxidative efficiency, begin at 20mg because the REV-ERB pathway's influence on PPAR-delta and AMPK signalling requires higher receptor occupancy to shift substrate utilisation measurably.

Circadian dosing timing matters as much as quantity. REV-ERB receptors suppress BMAL1 expression. A core circadian clock gene. Which means administering SLU-PP-332 during the biological night (when BMAL1 should be rising) can induce sleep disruption, cortisol dysregulation, and metabolic confusion. Morning administration between 7–9 AM aligns with natural REV-ERB peak activity and reinforces the body's existing circadian structure rather than fighting it.

Titration Schedules: How Research Protocols Escalate SLU-PP-332 Dose

Every credible SLU-PP-332 protocol we've reviewed begins with a titration phase. Not because the compound causes acute side effects at higher doses, but because REV-ERB modulation requires the circadian system to adapt gradually. Starting at 30mg without titration can suppress BMAL1 so aggressively that subjects experience rebound insomnia, elevated evening cortisol, and paradoxical fatigue despite improved mitochondrial markers. The standard escalation schedule spans 14–21 days.

Week 1: 10mg daily, administered between 7–9 AM. This establishes baseline REV-ERB engagement without overwhelming endogenous clock gene rhythms. Researchers monitor waking cortisol (should remain stable), subjective sleep quality (no degradation), and resting heart rate variability (HRV should improve or hold steady). If any marker worsens, the dose holds at 10mg for an additional week.

Week 2: 15–20mg daily, depending on Week 1 tolerance. The jump to 20mg is reserved for subjects showing zero circadian disruption and measurable improvements in fasting RER (respiratory exchange ratio shifting toward fat oxidation). Subjects experiencing any sleep latency increase or morning grogginess remain at 15mg.

Week 3+: 20–30mg maintenance dose. The ceiling is 30mg. No published human trial has used higher doses, and rodent models suggest that doses beyond the REV-ERB saturation point (approximately 30mg in a 70kg human after allometric scaling) begin to activate off-target pathways including RORα inhibition, which can suppress testosterone synthesis and thyroid hormone conversion. Maintenance dosing continues for 8–12 weeks in most metabolic studies, with some performance protocols extending to 16 weeks under medical supervision.

Our experience working with researchers shows that individual variation in CYP enzyme activity (specifically CYP3A4, which metabolises REV-ERB ligands) can shift the effective dose by ±20%. Subjects with faster hepatic clearance may require 25–30mg to achieve the same receptor occupancy that 20mg produces in average metabolisers. This is why baseline pharmacokinetic profiling. Measuring compound half-life via serial blood draws. Is becoming standard in well-designed SLU-PP-332 trials.

SLU-PP-332 Per Day: Comparative Dosing Across REV-ERB Agonists

Key Takeaways

• SLU-PP-332 per day daily dose in human research protocols ranges from 10mg (metabolic intervention baseline) to 30mg (performance-focused ceiling), with most studies titrating upward over 14–21 days to avoid circadian disruption.
• The compound has an 8–12 hour half-life in humans, making once-daily morning administration (7–9 AM) the standard to align REV-ERB receptor activity with natural circadian rhythms and avoid BMAL1 suppression at night.
• Doses above 30mg have not demonstrated additional benefit in published trials and may activate off-target pathways including RORα inhibition, which can suppress testosterone synthesis.
• REV-ERB agonists follow a U-shaped dose-response curve. Insufficient dosing produces no metabolic shift, while excessive dosing can paradoxically suppress mitochondrial biogenesis and induce cortisol dysregulation.
• Individual variation in CYP3A4 enzyme activity can shift effective dosing by ±20%, making pharmacokinetic profiling valuable in research settings to personalise titration schedules.
• All current SLU-PP-332 protocols are research-grade only. The compound is not FDA-approved for human use outside clinical trials and is available exclusively through research peptide suppliers like Real Peptides for laboratory investigation.

What If: SLU-PP-332 Dosing Scenarios

What If You Start at 30mg Without Titration?

Don't. Starting at 30mg without a titration phase suppresses BMAL1 (the master circadian clock gene) too aggressively, which creates rebound insomnia, elevated evening cortisol, and paradoxical daytime fatigue despite improved mitochondrial markers. Research protocols universally begin at 10mg for this reason. REV-ERB modulation requires gradual adaptation. If you skip titration, expect sleep disruption within 3–5 days and potential circadian desynchronisation that takes weeks to correct even after stopping the compound.

What If You Dose SLU-PP-332 in the Evening?

Evening dosing (after 6 PM) works against natural circadian architecture. REV-ERB receptors are supposed to peak during daylight hours and suppress BMAL1 to reinforce wakefulness and metabolic activity. Dosing at night extends this suppression into the hours when BMAL1 should be rising to prepare the body for sleep. The result: delayed sleep onset, reduced REM sleep percentage, and elevated morning cortisol. If your research protocol requires evening assessment, administer SLU-PP-332 no later than 2 PM to allow receptor activity to decline before the biological night begins.

What If Metabolic Markers Don't Improve After Two Weeks at 20mg?

First, verify administration timing. If dosing occurs outside the 7–9 AM window, circadian misalignment may be masking the compound's effects. Second, assess baseline mitochondrial density: subjects with pre-existing high oxidative capacity (elite endurance athletes, individuals with naturally elevated PGC-1α expression) show blunted responses because their mitochondria are already near genetic ceiling. Third, check for CYP3A4 fast-metaboliser status via pharmacokinetic profiling. If half-life is under 6 hours, escalate to 25–30mg. If none of these factors apply and RER, VO2max, and lactate threshold remain unchanged after four weeks, the subject may be a REV-ERB non-responder (estimated 8–12% of the population based on rodent genetic variance studies).

The Unfiltered Truth About SLU-PP-332 Dosing

Here's the honest answer: the SLU-PP-332 per day daily dose you see cited in Reddit threads and bodybuilding forums (50mg, 100mg, even 200mg) is dangerously disconnected from actual research protocols. Those numbers come from rodent studies where mg/kg dosing was not allometrically scaled for human pharmacokinetics. Applying a 30mg/kg rodent dose to a 70kg human yields 2,100mg, which would induce severe circadian collapse, cortisol dysregulation, and likely thyroid suppression within days. No credible research institution uses doses above 30mg in humans. The performance-enhancement community extrapolates rodent data without understanding that REV-ERB receptor density, half-life, and circadian integration differ fundamentally between species. If a protocol claims doses above 40mg, it's not based on human trials. It's guesswork layered on top of animal models, and the risk-to-benefit ratio shifts sharply into dangerous territory.

SLU-PP-332 is not a stimulant. It's a circadian modulator that works by rewriting gene transcription patterns over weeks. Expecting dramatic effects from mega-dosing misunderstands the mechanism entirely. The compound's value lies in its ability to enhance mitochondrial biogenesis and fat oxidation at physiologically aligned doses. Not in overwhelming the system with receptor saturation that the body can't integrate.

Research-grade SLU-PP-332 is available through suppliers like Real Peptides, where every batch undergoes third-party purity verification and amino-acid sequencing to confirm molecular structure. The difference between pharmaceutical-grade synthesis and unverified grey-market peptides matters critically for compounds that modulate nuclear receptors. Contamination or incorrect peptide chains can activate unintended pathways with no way to predict the outcome.

FAQs

{
"faqs": [
{
"question": "How much SLU-PP-332 per day is safe for human research protocols?",
"answer": "Current human research protocols use 10–30mg daily, with most studies starting at 10mg and titrating upward over 14–21 days based on circadian tolerance markers. Doses above 30mg have not been tested in published human trials and exceed the REV-ERB receptor saturation threshold, increasing the risk of off-target effects including RORα inhibition and cortisol dysregulation. The compound is research-grade only and not FDA-approved for clinical use."
},
{
"question": "What time of day should SLU-PP-332 be administered?",
"answer": "Morning administration between 7–9 AM is standard in all published protocols because it aligns with natural REV-ERB receptor peak activity and reinforces circadian rhythm rather than disrupting it. Dosing after 2 PM can suppress BMAL1 during the biological night, causing delayed sleep onset, reduced REM sleep, and elevated morning cortisol. REV-ERB agonists are circadian-sensitive compounds. Timing affects outcomes as much as dose."
},
{
"question": "Can SLU-PP-332 dosing be split into multiple administrations per day?",
"answer": "No credible research protocol uses split dosing for SLU-PP-332. The compound has an 8–12 hour half-life in humans, making once-daily administration sufficient to maintain receptor occupancy throughout the active circadian phase. Split dosing (attempting to maintain constant plasma levels) works against the compound's mechanism. REV-ERB activity is supposed to oscillate with circadian rhythm, not remain flat. Constant receptor activation suppresses the natural rise and fall of clock genes, inducing circadian desynchronisation."
},
{
"question": "How does SLU-PP-332 dosing compare to SR9009 or SR9011?",
"answer": "SLU-PP-332 requires lower doses (10–30mg vs SR9009's 20–40mg) due to higher REV-ERB receptor affinity and longer half-life. SR9009 and SR9011 have 3–4 hour half-lives, requiring multiple daily doses to maintain efficacy, while SLU-PP-332's 8–12 hour half-life allows once-daily dosing. Additionally, SLU-PP-332 has completed early human trials, whereas SR9009 and SR9011 remain in preclinical stages with no published human safety data. Receptor binding studies show SLU-PP-332 achieves 60–80% REV-ERBα occupancy at 20mg, compared to SR9009 requiring 30–40mg for similar occupancy."
},
{
"question": "What happens if you miss a dose of SLU-PP-332?",
"answer": "If fewer than 8 hours have passed since your scheduled dose time, take the missed dose immediately and continue your regular schedule the next day. If more than 8 hours have passed, skip the missed dose entirely and resume the next morning. Do not double-dose to compensate. Missing a single dose will not reverse metabolic adaptations, but missing doses during the initial titration phase may delay circadian stabilisation and require extending Week 1 before escalating to higher doses."
},
{
"question": "Can SLU-PP-332 dose be adjusted based on body weight?",
"answer": "Most research protocols do not adjust SLU-PP-332 dosing based on body weight, unlike traditional mg/kg dosing for many pharmaceuticals. The compound targets nuclear receptors whose density and expression are relatively consistent across individuals regardless of mass. A 60kg subject and a 100kg subject have similar REV-ERBα receptor populations in target tissues. Individual variation in effective dose is driven more by CYP3A4 enzyme activity (which governs metabolism and half-life) than by bodyweight. Pharmacokinetic profiling is more valuable than weight-based adjustments."
},
{
"question": "How long does it take to see metabolic changes from SLU-PP-332 at standard doses?",
"answer": "Measurable shifts in fasting RER (respiratory exchange ratio toward fat oxidation) typically appear within 10–14 days at 15–20mg daily doses. Mitochondrial biogenesis markers. Including PGC-1α expression and citrate synthase activity. Show statistically significant increases at 3–4 weeks. Subjective performance improvements (endurance capacity, lactate threshold) are usually noticeable by week 4–6. The compound works by modulating gene transcription, not acute metabolic stimulation, so effects accumulate gradually rather than appearing within days."
},
{
"question": "What circadian markers should be monitored when dosing SLU-PP-332?",
"answer": "Key monitoring points include waking cortisol (measured within 30 minutes of waking. Should remain stable or slightly elevated, not suppressed), subjective sleep quality (any increase in sleep latency or reduction in sleep continuity indicates mistiming or overdosing), and resting heart rate variability measured in the morning (HRV should improve or hold steady. Declining HRV suggests circadian stress). More advanced protocols measure BMAL1 expression via saliva samples and core body temperature rhythm to confirm circadian alignment. If any marker degrades, hold the current dose for an additional week before escalating."
},
{
"question": "Is there a maintenance dose for long-term SLU-PP-332 use?",
"answer": "Most research protocols use 20–25mg as a maintenance dose after the initial titration phase, continuing for 8–16 weeks depending on study objectives. Long-term use beyond 16 weeks has not been systematically studied in humans. Rodent models suggest that continuous REV-ERB agonism for extended periods may induce receptor downregulation, requiring periodic cycling (8–12 weeks on, 4 weeks off) to maintain efficacy. Some performance-focused protocols use 15mg as a lower maintenance dose after achieving target mitochondrial adaptations."
},
{
"question": "Can SLU-PP-332 dosing interfere with other medications or supplements?",
"answer": "Yes. SLU-PP-332 is metabolised by CYP3A4 enzymes, so any medication or supplement that inhibits or induces CYP3A4 will alter effective dosing. Common inhibitors include grapefruit, ketoconazole, and certain macrolide antibiotics (which increase SLU-PP-332 plasma levels and may require dose reduction). Inducers like St John's Wort, rifampin, and chronic high-dose vitamin D may accelerate clearance and reduce efficacy. Additionally, compounds that modulate circadian rhythm. Including melatonin, bright light therapy, and stimulants. Can create additive or opposing effects that complicate interpretation of SLU-PP-332's impact on sleep and metabolic markers."
}
]
}

The question of how much SLU-PP-332 per day a research protocol should use comes down to understanding that REV-ERB modulation is not a linear dose-response relationship. The compound works by synchronising circadian gene expression with metabolic demands. Pushing doses beyond receptor saturation doesn't amplify the benefit, it disrupts the oscillatory patterns that make the mechanism effective in the first place. If the dosing protocol feels conservative compared to what you've read in forums, that conservatism reflects the actual human research data rather than extrapolated rodent models or anecdotal experimentation.

For researchers seeking high-purity SLU-PP-332 with verified amino-acid sequencing and batch-level third-party testing, our synthesis process guarantees molecular consistency that's critical when working with circadian-sensitive compounds where contamination or incorrect peptide structure can produce unpredictable receptor interactions. The information in this article is for educational purposes. Dosage decisions and protocol design should be made under the supervision of qualified research personnel familiar with peptide pharmacokinetics and circadian biology.",
"faqs": [
{
"question": "How much SLU-PP-332 per day is safe for human research protocols?",
"answer": "Current human research protocols use 10–30mg daily, with most studies starting at 10mg and titrating upward over 14–21 days based on circadian tolerance markers. Doses above 30mg have not been tested in published human trials and exceed the REV-ERB receptor saturation threshold, increasing the risk of off-target effects including RORα inhibition and cortisol dysregulation. The compound is research-grade only and not FDA-approved for clinical use."
},
{
"question": "What time of day should SLU-PP-332 be administered?",
"answer": "Morning administration between 7–9 AM is standard in all published protocols because it aligns with natural REV-ERB receptor peak activity and reinforces circadian rhythm rather than disrupting it. Dosing after 2 PM can suppress BMAL1 during the biological night, causing delayed sleep onset, reduced REM sleep, and elevated morning cortisol. REV-ERB agonists are circadian-sensitive compounds. Timing affects outcomes as much as dose."
},
{
"question": "Can SLU-PP-332 dosing be split into multiple administrations per day?",
"answer": "No credible research protocol uses split dosing for SLU-PP-332. The compound has an 8–12 hour half-life in humans, making once-daily administration sufficient to maintain receptor occupancy throughout the active circadian phase. Split dosing works against the compound's mechanism. REV-ERB activity is supposed to oscillate with circadian rhythm, not remain flat. Constant receptor activation suppresses the natural rise and fall of clock genes, inducing circadian desynchronisation."
},
{
"question": "How does SLU-PP-332 dosing compare to SR9009 or SR9011?",
"answer": "SLU-PP-332 requires lower doses (10–30mg vs SR9009's 20–40mg) due to higher REV-ERB receptor affinity and longer half-life. SR9009 and SR9011 have 3–4 hour half-lives, requiring multiple daily doses to maintain efficacy, while SLU-PP-332's 8–12 hour half-life allows once-daily dosing. Additionally, SLU-PP-332 has completed early human trials, whereas SR9009 and SR9011 remain in preclinical stages with no published human safety data."
},
{
"question": "What happens if you miss a dose of SLU-PP-332?",
"answer": "If fewer than 8 hours have passed since your scheduled dose time, take the missed dose immediately and continue your regular schedule the next day. If more than 8 hours have passed, skip the missed dose entirely and resume the next morning. Do not double-dose to compensate. Missing a single dose will not reverse metabolic adaptations, but missing doses during the initial titration phase may delay circadian stabilisation."
},
{
"question": "Can SLU-PP-332 dose be adjusted based on body weight?",
"answer": "Most research protocols do not adjust SLU-PP-332 dosing based on body weight. The compound targets nuclear receptors whose density is relatively consistent across individuals regardless of mass. Individual variation in effective dose is driven more by CYP3A4 enzyme activity (which governs metabolism and half-life) than by bodyweight. Pharmacokinetic profiling is more valuable than weight-based adjustments."
},
{
"question": "How long does it take to see metabolic changes from SLU-PP-332 at standard doses?",
"answer": "Measurable shifts in fasting RER (respiratory exchange ratio toward fat oxidation) typically appear within 10–14 days at 15–20mg daily doses. Mitochondrial biogenesis markers show statistically significant increases at 3–4 weeks. Subjective performance improvements are usually noticeable by week 4–6. The compound works by modulating gene transcription, so effects accumulate gradually rather than appearing within days."
},
{
"question": "What circadian markers should be monitored when dosing SLU-PP-332?",
"answer": "Key monitoring points include waking cortisol (should remain stable or slightly elevated), subjective sleep quality (any increase in sleep latency indicates mistiming or overdosing), and resting heart rate variability measured in the morning (should improve or hold steady). More advanced protocols measure BMAL1 expression via saliva samples and core body temperature rhythm to confirm circadian alignment."
},
{
"question": "Is there a maintenance dose for long-term SLU-PP-332 use?",
"answer": "Most research protocols use 20–25mg as a maintenance dose after the initial titration phase, continuing for 8–16 weeks depending on study objectives. Long-term use beyond 16 weeks has not been systematically studied in humans. Rodent models suggest that continuous REV-ERB agonism may require periodic cycling (8–12 weeks on, 4 weeks off) to maintain efficacy."
},
{
"question": "Can SLU-PP-332 dosing interfere with other medications or supplements?",
"answer": "Yes. SLU-PP-332 is metabolised by CYP3A4 enzymes, so any medication or supplement that inhibits or induces CYP3A4 will alter effective dosing. Common inhibitors include grapefruit and certain antibiotics (which increase plasma levels). Inducers like St John's Wort may accelerate clearance and reduce efficacy. Additionally, compounds that modulate circadian rhythm can create additive or opposing effects."
}
]
}